 | • レポートコード：QYR9ST02932 • 出版社/出版日：QYResearch / 2019年9月2日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、113ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医薬品・医療 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| ※本調査レポートでは、世界のラタムアダリムマブ市場について調査・分析し、以下の構成でお届け致します。ラタムアダリムマブの種類別には、経口タイプ、注射タイプに、用途別には、関節リウマチ、乾癬、クローン病、潰瘍性大腸炎、その他に、地域別には、北米、アメリカ、ヨーロッパ、アジア、中国、日本国内、韓国、インド、中南米、中東・アフリカなどに区分してセグメント分析を行いました。 ・調査販売 ・エグゼクティブ・サマリー ・企業別ラタムアダリムマブ売上データ ・地域別ラタムアダリムマブ市場規模：北米、アメリカ、ヨーロッパ、アジア、中国、日本国内、韓国、インド、中南米、中東・アフリカ、その他 ・種類別ラタムアダリムマブ市場規模：経口タイプ、注射タイプ ・用途別ラタムアダリムマブ市場規模：関節リウマチ、乾癬、クローン病、潰瘍性大腸炎、その他 ・主要メーカーの企業情報：AbbVie, Inc.、Amgen, Inc.、Boehringer Ingelheim GmbH、Eisai Co., Ltd.、Mylan N.V.、Novartis AG、Pfizer, Inc. ・ラタムアダリムマブの市場規模予測 ・バリューチェーン及び販売チャネル分析 ・市場機会・課題・リスク・影響因子分析 ... |
Adalimumab was first approved in the U.S. for the treatment of aforementioned medical conditions. Currently, this is marketed in more than 60 countries. However, owing to the biologic nature of the drug, it results in high cost and low accessibility in emerging economies such as LATAM and Asia Pacific. On the other hand, with the probable entry of the adalimumab biosimilars post the patent expiry the low costs up to less than 25% to 35% of the originator drugs will boost the uptake and prescription of adalimumab for the treatment of above mentioned medical conditions.Consistent technological sophistications in development of biosimilar followed by increasing incidence and prevalence of various medical conditions have rendered encouraging growth opportunities for various biological drugs and other innovative biopharmaceuticals. The LATAM adalimumab market by application has been categorized on the basis of the usage of adalimumab for treatment of various medical conditions.
The global LATAM Adalimumab market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the LATAM Adalimumab market based on company, product type, end user and key regions.
This report studies the global market size of LATAM Adalimumab in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of LATAM Adalimumab in these regions.
This research report categorizes the global LATAM Adalimumab market by top players/brands, region, type and end user. This report also studies the global LATAM Adalimumab market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
AbbVie, Inc.
Amgen, Inc.
Boehringer Ingelheim GmbH
Eisai Co., Ltd.
Mylan N.V.
Novartis AG
Pfizer, Inc.
Market size by Product
Oral Type
Injection Type
Market size by End User
Rheumatoid Arthritis
Psoriasis
Crohn’s Disease
Ulcerative Colitis
Others
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global LATAM Adalimumab market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of LATAM Adalimumab market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global LATAM Adalimumab companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of LATAM Adalimumab submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of LATAM Adalimumab are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of LATAM Adalimumab market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
レポート目次Table of Contents
1 Study Coverage
1.1 LATAM Adalimumab Product
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global LATAM Adalimumab Market Size Growth Rate by Product
1.4.2 Oral Type
1.4.3 Injection Type
1.5 Market by End User
1.5.1 Global LATAM Adalimumab Market Size Growth Rate by End User
1.5.2 Rheumatoid Arthritis
1.5.3 Psoriasis
1.5.4 Crohn’s Disease
1.5.5 Ulcerative Colitis
1.5.6 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global LATAM Adalimumab Market Size
2.1.1 Global LATAM Adalimumab Revenue 2014-2025
2.1.2 Global LATAM Adalimumab Sales 2014-2025
2.2 LATAM Adalimumab Growth Rate by Regions
2.2.1 Global LATAM Adalimumab Sales by Regions
2.2.2 Global LATAM Adalimumab Revenue by Regions
3 Breakdown Data by Manufacturers
3.1 LATAM Adalimumab Sales by Manufacturers
3.1.1 LATAM Adalimumab Sales by Manufacturers
3.1.2 LATAM Adalimumab Sales Market Share by Manufacturers
3.1.3 Global LATAM Adalimumab Market Concentration Ratio (CR5 and HHI)
3.2 LATAM Adalimumab Revenue by Manufacturers
3.2.1 LATAM Adalimumab Revenue by Manufacturers (2014-2019)
3.2.2 LATAM Adalimumab Revenue Share by Manufacturers (2014-2019)
3.3 LATAM Adalimumab Price by Manufacturers
3.4 LATAM Adalimumab Manufacturing Base Distribution, Product Types
3.4.1 LATAM Adalimumab Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers LATAM Adalimumab Product Type
3.4.3 Date of International Manufacturers Enter into LATAM Adalimumab Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
4.1 Global LATAM Adalimumab Sales by Product
4.2 Global LATAM Adalimumab Revenue by Product
4.3 LATAM Adalimumab Price by Product
5 Breakdown Data by End User
5.1 Overview
5.2 Global LATAM Adalimumab Breakdown Data by End User
6 North America
6.1 North America LATAM Adalimumab by Countries
6.1.1 North America LATAM Adalimumab Sales by Countries
6.1.2 North America LATAM Adalimumab Revenue by Countries
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America LATAM Adalimumab by Product
6.3 North America LATAM Adalimumab by End User
7 Europe
7.1 Europe LATAM Adalimumab by Countries
7.1.1 Europe LATAM Adalimumab Sales by Countries
7.1.2 Europe LATAM Adalimumab Revenue by Countries
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe LATAM Adalimumab by Product
7.3 Europe LATAM Adalimumab by End User
8 Asia Pacific
8.1 Asia Pacific LATAM Adalimumab by Countries
8.1.1 Asia Pacific LATAM Adalimumab Sales by Countries
8.1.2 Asia Pacific LATAM Adalimumab Revenue by Countries
8.1.3 China
8.1.4 Japan
8.1.5 Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Malaysia
8.1.10 Philippines
8.1.11 Thailand
8.1.12 Vietnam
8.1.13 Singapore
8.2 Asia Pacific LATAM Adalimumab by Product
8.3 Asia Pacific LATAM Adalimumab by End User
9 Central & South America
9.1 Central & South America LATAM Adalimumab by Countries
9.1.1 Central & South America LATAM Adalimumab Sales by Countries
9.1.2 Central & South America LATAM Adalimumab Revenue by Countries
9.1.3 Brazil
9.2 Central & South America LATAM Adalimumab by Product
9.3 Central & South America LATAM Adalimumab by End User
10 Middle East and Africa
10.1 Middle East and Africa LATAM Adalimumab by Countries
10.1.1 Middle East and Africa LATAM Adalimumab Sales by Countries
10.1.2 Middle East and Africa LATAM Adalimumab Revenue by Countries
10.1.3 GCC Countries
10.1.4 Turkey
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa LATAM Adalimumab by Product
10.3 Middle East and Africa LATAM Adalimumab by End User
11 Company Profiles
11.1 AbbVie, Inc.
11.1.1 AbbVie, Inc. Company Details
11.1.2 Company Business Overview
11.1.3 AbbVie, Inc. LATAM Adalimumab Sales, Revenue and Gross Margin (2014-2019)
11.1.4 AbbVie, Inc. LATAM Adalimumab Products Offered
11.1.5 AbbVie, Inc. Recent Development
11.2 Amgen, Inc.
11.2.1 Amgen, Inc. Company Details
11.2.2 Company Business Overview
11.2.3 Amgen, Inc. LATAM Adalimumab Sales, Revenue and Gross Margin (2014-2019)
11.2.4 Amgen, Inc. LATAM Adalimumab Products Offered
11.2.5 Amgen, Inc. Recent Development
11.3 Boehringer Ingelheim GmbH
11.3.1 Boehringer Ingelheim GmbH Company Details
11.3.2 Company Business Overview
11.3.3 Boehringer Ingelheim GmbH LATAM Adalimumab Sales, Revenue and Gross Margin (2014-2019)
11.3.4 Boehringer Ingelheim GmbH LATAM Adalimumab Products Offered
11.3.5 Boehringer Ingelheim GmbH Recent Development
11.4 Eisai Co., Ltd.
11.4.1 Eisai Co., Ltd. Company Details
11.4.2 Company Business Overview
11.4.3 Eisai Co., Ltd. LATAM Adalimumab Sales, Revenue and Gross Margin (2014-2019)
11.4.4 Eisai Co., Ltd. LATAM Adalimumab Products Offered
11.4.5 Eisai Co., Ltd. Recent Development
11.5 Mylan N.V.
11.5.1 Mylan N.V. Company Details
11.5.2 Company Business Overview
11.5.3 Mylan N.V. LATAM Adalimumab Sales, Revenue and Gross Margin (2014-2019)
11.5.4 Mylan N.V. LATAM Adalimumab Products Offered
11.5.5 Mylan N.V. Recent Development
11.6 Novartis AG
11.6.1 Novartis AG Company Details
11.6.2 Company Business Overview
11.6.3 Novartis AG LATAM Adalimumab Sales, Revenue and Gross Margin (2014-2019)
11.6.4 Novartis AG LATAM Adalimumab Products Offered
11.6.5 Novartis AG Recent Development
11.7 Pfizer, Inc.
11.7.1 Pfizer, Inc. Company Details
11.7.2 Company Business Overview
11.7.3 Pfizer, Inc. LATAM Adalimumab Sales, Revenue and Gross Margin (2014-2019)
11.7.4 Pfizer, Inc. LATAM Adalimumab Products Offered
11.7.5 Pfizer, Inc. Recent Development
12 Future Forecast
12.1 LATAM Adalimumab Market Forecast by Regions
12.1.1 Global LATAM Adalimumab Sales Forecast by Regions 2019-2025
12.1.2 Global LATAM Adalimumab Revenue Forecast by Regions 2019-2025
12.2 LATAM Adalimumab Market Forecast by Product
12.2.1 Global LATAM Adalimumab Sales Forecast by Product 2019-2025
12.2.2 Global LATAM Adalimumab Revenue Forecast by Product 2019-2025
12.3 LATAM Adalimumab Market Forecast by End User
12.4 North America LATAM Adalimumab Forecast
12.5 Europe LATAM Adalimumab Forecast
12.6 Asia Pacific LATAM Adalimumab Forecast
12.7 Central & South America LATAM Adalimumab Forecast
12.8 Middle East and Africa LATAM Adalimumab Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 LATAM Adalimumab Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Figure LATAM Adalimumab Product Picture
Table LATAM Adalimumab Market Segments
Table Key Manufacturers LATAM Adalimumab Covered
Table Global LATAM Adalimumab Market Size Growth Rate by Product 2019-2025 (K Units) & (Million US$)
Figure Global LATAM Adalimumab Sales Market Share by Product 2014-2025
Figure Oral Type Product Picture
Table Major Manufacturers of Oral Type
Figure Injection Type Product Picture
Table Major Manufacturers of Injection Type
Table Global LATAM Adalimumab Market Size Growth Rate by End User 2019-2025 (K Units)
Figure Rheumatoid Arthritis
Figure Psoriasis
Figure Crohn’s Disease
Figure Ulcerative Colitis
Figure Others
Figure LATAM Adalimumab Report Years Considered
Figure Global LATAM Adalimumab Market Size 2014-2025 (Million US$)
Figure Global LATAM Adalimumab Sales 2014-2025 (K Units)
Table Global LATAM Adalimumab Market Size by Regions 2014-2019 (K Units) & (Million US$)
Table Global LATAM Adalimumab Sales by Regions 2014-2019 (K Units)
Table Global LATAM Adalimumab Sales Market Share by Regions 2014-2019
Figure Global LATAM Adalimumab Sales Market Share by Regions 2014-2019
Figure 2018 Global LATAM Adalimumab Sales Market Share by Regions
Table Global LATAM Adalimumab Revenue by Regions 2014-2019 (Million US$)
Table Global LATAM Adalimumab Revenue Market Share by Regions 2014-2019
Figure Global LATAM Adalimumab Revenue Market Share by Regions 2014-2019
Figure 2018 Global LATAM Adalimumab Revenue Market Share by Regions
Table Global LATAM Adalimumab Sales by Manufacturers (2014-2019) (K Units)
Table Global LATAM Adalimumab Sales Share by Manufacturers (2014-2019)
Figure Global LATAM Adalimumab Sales Share by Manufacturers in 2018
Table Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table LATAM Adalimumab Revenue by Manufacturers (2014-2019) (Million USD)
Table LATAM Adalimumab Revenue Share by Manufacturers (2014-2019)
Figure LATAM Adalimumab Value Share by Manufacturers in 2018
Table Key Manufacturers LATAM Adalimumab Price (2014-2019) (USD/Unit)
Table LATAM Adalimumab Manufacturers Manufacturing Base Distribution and Headquarters
Table Manufacturers LATAM Adalimumab Product Type
Table Date of International Manufacturers Enter into LATAM Adalimumab Market
Table Manufacturers Mergers & Acquisitions, Expansion Plans
Table Global LATAM Adalimumab Sales by Product (2014-2019) (K Units)
Table Global LATAM Adalimumab Sales Share by Product (2014-2019)
Figure Global LATAM Adalimumab Sales Market Share by Product (2014-2019)
Figure Global LATAM Adalimumab Sales Market Share by Product in 2018
Table Global LATAM Adalimumab Revenue by Product (2014-2019) (Million US$)
Table Global LATAM Adalimumab Revenue Share by Product (2014-2019)
Figure Global LATAM Adalimumab Revenue Market Share by Product (2014-2019)
Figure Global LATAM Adalimumab Revenue Market Share by Product in 2018
Table LATAM Adalimumab Price by Product 2014-2019 (USD/Unit)
Table Global LATAM Adalimumab Sales by End User (2014-2019) (K Units)
Table Global LATAM Adalimumab Sales Share by End User (2014-2019)
Figure Global Sales LATAM Adalimumab Market Share by End User (2014-2019)
Figure Global Sales LATAM Adalimumab Market Share by End User in 2018
Figure North America LATAM Adalimumab Sales Growth Rate 2014-2019 (K Units)
Figure North America LATAM Adalimumab Revenue Growth Rate 2014-2019 (Million US$)
Table North America LATAM Adalimumab Sales by Countries (2014-2019) (K Units)
Table North America LATAM Adalimumab Sales Market Share by Countries (2014-2019)
Figure 2018 North America LATAM Adalimumab Sales Market Share by Countries
Table North America LATAM Adalimumab Revenue by Countries (2014-2019) (Million US$)
Table North America LATAM Adalimumab Revenue Market Share by Countries (2014-2019)
Figure 2018 North America LATAM Adalimumab Revenue Market Share by Countries
Figure United States LATAM Adalimumab Sales Growth Rate (2014-2019) (K Units)
Figure United States LATAM Adalimumab Revenue Growth Rate (2014-2019) (K Units)
Figure Canada LATAM Adalimumab Sales Growth Rate (2014-2019) (K Units)
Figure Canada LATAM Adalimumab Revenue Growth Rate (2014-2019) (Million US$)
Figure Mexico LATAM Adalimumab Sales Growth Rate (2014-2019) (K Units)
Figure Mexico LATAM Adalimumab Revenue Growth Rate (2014-2019) (Million US$)
Table North America LATAM Adalimumab Sales by Product (2014-2019) (K Units)
Table North America LATAM Adalimumab Sales Market Share by Product (2014-2019)
Figure 2018 North America LATAM Adalimumab Market Share by Product
Table North America LATAM Adalimumab Sales by End User (2014-2019) (K Units)
Table North America LATAM Adalimumab Sales Market Share by End User (2014-2019)
Figure 2018 North America LATAM Adalimumab Market Share by End User
Figure Europe LATAM Adalimumab Sales Growth Rate 2014-2019 (K Units)
Figure Europe LATAM Adalimumab Revenue Growth Rate 2014-2019 (Million US$)
Table Europe LATAM Adalimumab Sales by Countries (2014-2019) (K Units)
Table Europe LATAM Adalimumab Sales Market Share by Countries (2014-2019)
Figure 2018 Europe LATAM Adalimumab Sales Market Share by Countries
Table Europe LATAM Adalimumab Revenue by Countries (2014-2019) (Million US$)
Table Europe LATAM Adalimumab Revenue Market Share by Countries (2014-2019)
Figure 2018 Europe LATAM Adalimumab Revenue Market Share by Countries
Figure Germany LATAM Adalimumab Sales Growth Rate (2014-2019) (K Units)
Figure Germany LATAM Adalimumab Revenue Growth Rate (2014-2019) (Million US$)
Figure France LATAM Adalimumab Sales Growth Rate (2014-2019) (K Units)
Figure France LATAM Adalimumab Revenue Growth Rate (2014-2019) (Million US$)
Figure UK LATAM Adalimumab Sales Growth Rate (2014-2019) (K Units)
Figure UK LATAM Adalimumab Revenue Growth Rate (2014-2019) (Million US$)
Figure Italy LATAM Adalimumab Sales Growth Rate (2014-2019) (K Units)
Figure Italy LATAM Adalimumab Revenue Growth Rate (2014-2019) (Million US$)
Figure Russia LATAM Adalimumab Sales Growth Rate (2014-2019) (K Units)
Figure Russia LATAM Adalimumab Revenue Growth Rate (2014-2019) (Million US$)
Table Europe LATAM Adalimumab Sales by Product (2014-2019) (K Units)
Table Europe LATAM Adalimumab Sales Market Share by Product (2014-2019)
Figure 2018 Europe LATAM Adalimumab Market Share by Product
Table Europe LATAM Adalimumab Sales by End User (2014-2019) (K Units)
Table Europe LATAM Adalimumab Sales Market Share by End User (2014-2019)
Figure 2018 Europe LATAM Adalimumab Market Share by End User
Figure Asia Pacific LATAM Adalimumab Sales Growth Rate 2014-2019 (K Units)
Figure Asia Pacific LATAM Adalimumab Revenue Growth Rate 2014-2019 (Million US$)
Table Asia Pacific LATAM Adalimumab Sales by Countries (2014-2019) (K Units)
Table Asia Pacific LATAM Adalimumab Sales Market Share by Countries (2014-2019)
Figure 2018 Asia Pacific LATAM Adalimumab Sales Market Share by Countries
Table Asia Pacific LATAM Adalimumab Revenue by Countries (2014-2019) (Million US$)
Table Asia Pacific LATAM Adalimumab Revenue Market Share by Countries (2014-2019)
Figure 2018 Asia Pacific LATAM Adalimumab Revenue Market Share by Countries
Figure China LATAM Adalimumab Sales Growth Rate (2014-2019) (K Units)
Figure China LATAM Adalimumab Revenue Growth Rate (2014-2019) (Million US$)
Figure Japan LATAM Adalimumab Sales Growth Rate (2014-2019) (K Units)
Figure Japan LATAM Adalimumab Revenue Growth Rate (2014-2019) (Million US$)
Figure Korea LATAM Adalimumab Sales Growth Rate (2014-2019) (K Units)
Figure Korea LATAM Adalimumab Revenue Growth Rate (2014-2019) (Million US$)
Figure India LATAM Adalimumab Sales Growth Rate (2014-2019) (K Units)
Figure India LATAM Adalimumab Revenue Growth Rate (2014-2019) (Million US$)
Figure Australia LATAM Adalimumab Sales Growth Rate (2014-2019) (K Units)
Figure Australia LATAM Adalimumab Revenue Growth Rate (2014-2019) (Million US$)
Figure Indonesia LATAM Adalimumab Sales Growth Rate (2014-2019) (K Units)
Figure Indonesia LATAM Adalimumab Revenue Growth Rate (2014-2019) (Million US$)
Figure Malaysia LATAM Adalimumab Sales Growth Rate (2014-2019) (K Units)
Figure Malaysia LATAM Adalimumab Revenue Growth Rate (2014-2019) (Million US$)
Figure Philippines LATAM Adalimumab Sales Growth Rate (2014-2019) (K Units)
Figure Philippines LATAM Adalimumab Revenue Growth Rate (2014-2019) (Million US$)
Figure Thailand LATAM Adalimumab Sales Growth Rate (2014-2019) (K Units)
Figure Thailand LATAM Adalimumab Revenue Growth Rate (2014-2019) (Million US$)
Figure Vietnam LATAM Adalimumab Sales Growth Rate (2014-2019) (K Units)
Figure Vietnam LATAM Adalimumab Revenue Growth Rate (2014-2019) (Million US$)
Figure Singapore LATAM Adalimumab Sales Growth Rate (2014-2019) (K Units)
Figure Singapore LATAM Adalimumab Revenue Growth Rate (2014-2019) (Million US$)
Table Asia Pacific LATAM Adalimumab Sales by Product (2014-2019) (K Units)
Table Asia Pacific LATAM Adalimumab Sales Market Share by Product (2014-2019)
Figure 2018 Asia Pacific LATAM Adalimumab Market Share by Product
Table Asia Pacific LATAM Adalimumab Sales by End User (2014-2019) (K Units)
Table Asia Pacific LATAM Adalimumab Sales Market Share by End User (2014-2019)
Figure 2018 Asia Pacific LATAM Adalimumab Market Share by End User
Figure Central & South America LATAM Adalimumab Sales Growth Rate 2014-2019 (K Units)
Figure Central & South America LATAM Adalimumab Revenue Growth Rate 2014-2019 (Million US$)
Table Central & South America LATAM Adalimumab Sales by Countries (2014-2019) (K Units)
Table Central & South America LATAM Adalimumab Sales Market Share by Countries (2014-2019)
Figure 2018 Central & South America LATAM Adalimumab Sales Market Share by Countries
Table Central & South America LATAM Adalimumab Revenue by Countries (2014-2019) (Million US$)
Table Central & South America LATAM Adalimumab Revenue Market Share by Countries (2014-2019)
Figure 2018 Central & South America LATAM Adalimumab Revenue Market Share by Countries
Figure Brazil LATAM Adalimumab Sales Growth Rate (2014-2019) (K Units)
Figure Brazil LATAM Adalimumab Revenue Growth Rate (2014-2019) (Million US$)
Figure Argentina LATAM Adalimumab Sales Growth Rate (2014-2019) (K Units)
Figure Argentina LATAM Adalimumab Revenue Growth Rate (2014-2019) (Million US$)
Table Central & South America LATAM Adalimumab Sales by Product (2014-2019) (K Units)
Table Central & South America LATAM Adalimumab Sales Market Share by Product (2014-2019)
Figure 2018 Central & South America LATAM Adalimumab Market Share by Product
Table Central & South America LATAM Adalimumab Sales by End User (2014-2019) (K Units)
Table Central & South America LATAM Adalimumab Sales Market Share by End User (2014-2019)
Figure 2018 Central & South America LATAM Adalimumab Market Share by End User
Figure Middle East and Africa LATAM Adalimumab Sales Growth Rate 2014-2019 (K Units)
Figure Middle East and Africa LATAM Adalimumab Revenue Growth Rate 2014-2019 (Million US$)
Table Middle East and Africa LATAM Adalimumab Sales by Countries (2014-2019) (K Units)
Table Middle East and Africa LATAM Adalimumab Sales Market Share by Countries (2014-2019)
Figure 2018 Middle East and Africa LATAM Adalimumab Sales Market Share by Countries
Table Middle East and Africa LATAM Adalimumab Revenue by Countries (2014-2019) (Million US$)
Table Middle East and Africa LATAM Adalimumab Revenue Market Share by Countries (2014-2019)
Figure 2018 Middle East and Africa LATAM Adalimumab Revenue Market Share by Countries
Figure GCC Countries LATAM Adalimumab Sales Growth Rate (2014-2019) (K Units)
Figure GCC Countries LATAM Adalimumab Revenue Growth Rate (2014-2019) (Million US$)
Figure Turkey LATAM Adalimumab Sales Growth Rate (2014-2019) (K Units)
Figure Turkey LATAM Adalimumab Revenue Growth Rate (2014-2019) (Million US$)
Figure Egypt LATAM Adalimumab Sales Growth Rate (2014-2019) (K Units)
Figure Egypt LATAM Adalimumab Revenue Growth Rate (2014-2019) (Million US$)
Figure South Africa LATAM Adalimumab Sales Growth Rate (2014-2019) (K Units)
Figure South Africa LATAM Adalimumab Revenue Growth Rate (2014-2019) (Million US$)
Table Middle East and Africa LATAM Adalimumab Sales by Product (2014-2019) (K Units)
Table Middle East and Africa LATAM Adalimumab Sales Market Share by Product (2014-2019)
Figure 2018 Middle East and Africa LATAM Adalimumab Market Share by Product
Table Middle East and Africa LATAM Adalimumab Sales by End User (2014-2019) (K Units)
Table Middle East and Africa LATAM Adalimumab Sales Market Share by End User (2014-2019)
Figure 2018 Middle East and Africa LATAM Adalimumab Market Share by End User
Table AbbVie, Inc. Company Details
Table AbbVie, Inc. LATAM Adalimumab Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table AbbVie, Inc. Recent Development
Table Amgen, Inc. Company Details
Table Amgen, Inc. LATAM Adalimumab Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table Amgen, Inc. Recent Development
Table Boehringer Ingelheim GmbH Company Details
Table Boehringer Ingelheim GmbH LATAM Adalimumab Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table Boehringer Ingelheim GmbH Recent Development
Table Eisai Co., Ltd. Company Details
Table Eisai Co., Ltd. LATAM Adalimumab Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table Eisai Co., Ltd. Recent Development
Table Mylan N.V. Company Details
Table Mylan N.V. LATAM Adalimumab Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table Mylan N.V. Recent Development
Table Novartis AG Company Details
Table Novartis AG LATAM Adalimumab Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table Novartis AG Recent Development
Table Pfizer, Inc. Company Details
Table Pfizer, Inc. LATAM Adalimumab Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table Pfizer, Inc. Recent Development
Table Global LATAM Adalimumab Sales Forecast by Regions 2019-2025 (K Units)
Table Global LATAM Adalimumab Sales Market Share Forecast by Regions 2019-2025
Table Global LATAM Adalimumab Revenue Forecast by Regions 2019-2025 (Million US$)
Table Global LATAM Adalimumab Revenue Market Share Forecast by Regions 2019-2025
Table Global LATAM Adalimumab Sales Forecast by Product 2019-2025 (K Units)
Table Global LATAM Adalimumab Sales Market Share Forecast by Product 2019-2025
Table Global LATAM Adalimumab Revenue Forecast by Product 2019-2025 (Million US$)
Table Global LATAM Adalimumab Revenue Market Share Forecast by Product 2019-2025
Table Global LATAM Adalimumab Sales Forecast by End User 2019-2025 (K Units)
Table Global LATAM Adalimumab Sales Market Share Forecast by End User 2019-2025
Figure North America LATAM Adalimumab Sales Growth Rate Forecast (2019-2025) (K Units)
Figure North America LATAM Adalimumab Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Europe LATAM Adalimumab Sales Growth Rate Forecast (2019-2025) (K Units)
Figure Europe LATAM Adalimumab Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Asia Pacific LATAM Adalimumab Sales Growth Rate Forecast (2019-2025) (K Units)
Figure Asia Pacific LATAM Adalimumab Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Central & South America LATAM Adalimumab Sales Growth Rate Forecast (2019-2025) (K Units)
Figure Central & South America LATAM Adalimumab Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Middle East and Africa LATAM Adalimumab Sales Growth Rate Forecast (2019-2025) (K Units)
Figure Middle East and Africa LATAM Adalimumab Revenue Growth Rate Forecast (2019-2025) (Million US$)
Table LATAM Adalimumab Value Chain
Table LATAM Adalimumab Customers List
Table LATAM Adalimumab Distributors List
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources
関節リウマチ薬の世界市場：インサイト・予測 Rheumatoid Arthritis Drugs include prescription and OTC.The increasing prevalence of arthritis, the increasing acceptance of biopharmaceuticals, and the development of clear regulatory guidelines are major trends that are expected to trigger market growth. The global Rheumatoid Arthritis Drugs marke…- 関節リウマチ用薬の世界市場：インサイト・予測 Rheumatoid arthritis can be difficult to diagnose in its early stages because the early signs and symptoms mimic those of many other diseases. There is no one blood test or physical finding to confirm the diagnosis.The global Drugs for Rheumatoid Arthritis market is valued at xx million US$ in 2018 …
- 関節リウマチ治療薬の世界市場：市場規模・現状・予測 In 2018, the global Rheumatoid Arthritis Therapeutics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025. This report focuses on the global Rheumatoid Arthritis Therapeutics status, future forecast, growth opportunity, ke…
- 炎症性腸疾患薬の世界市場：インサイト・予測 Inflammatory bowel disease is a condition generally caused when immune system attacks harmless bacteria, virus, or food in the intestine. The most common inflammatory bowel diseases are ulcerative colitis and Crohns disease. The growth in prevalence of inflammatory bowel diseases such as ulcerative …
- セリアック病の世界市場：インサイト・予測 Celiac disease is a serious autoimmune disorder that can occur in genetically predisposed people where the ingestion of gluten leads to damage in the small intestine. It is estimated to affect 1 in 100 people worldwide.The global Celiac Disease market is valued at 130 million US$ in 2018 and will re…